Patents-Review.com
ClassID:

21031 ⎘

A61K38/4813 - CPC Classification

Classification description:

Medicinal preparations containing peptides; Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof; Enzymes; Proenzymes; Derivatives thereof; Hydrolases (3) acting on peptide bonds (3.4) Exopeptidases (3.4.11. to 3.4.19)

Recent Application in this class:
#1
20260102474
2026-04-16

MODIFIED ACE2 PROTEINS WITH IMPROVED ACTIVITY AGAINST SARS-COV-2

 #2
20260091066
2026-04-02

METHOD FOR PREVENTING INFECTION OF A HEALTHY PERSON OR A HEALTHY ANIMAL WITH A VIRUS THAT USES ACE2 AS A RECEPTOR, BINDING INHIBITOR AND MEDICAL DEVICE

 #3
20260055208
2026-02-26

COMBINATION OF GARADACIMAB AND PROLIDASE FOR CANCER THERAPY

 #4
20260000610
2026-01-01

NANODISC COMPRISING MEMBRANE SCAFFOLD PROTEIN HAVING FC REGION OF ANTIBODY FUSED THERETO

 #5
20250367270
2025-12-04

SYMMETRY BASED VIRAL ANTAGONISTS

 #6
20250338833
2025-11-06

METHODS FOR TREATING LYSOSOMAL STORAGE DISEASES

 #7
20250268994
2025-08-28

Optimized Nucleotide Sequences Encoding the Extracellular Domain of Human ACE2 Protein or a Portion Thereof

 #8
20250152681
2025-05-15

NANODISC COMPRISING ANGIOTENSIN CONVERTING ENZYME 2

 #9
20250135033
2025-05-01

COMPOSITIONS AND METHODS FOR TREATING SIALIDOSIS

 #10
20250082737
2025-03-13

ACE2 FUSION PROTEINS AND USES THEREOF

 #11
20250009854
2025-01-09

Antiviral Agent Comprising a Cellular Entry Receptor and Fc Region Component

 #12
20250009853
2025-01-09

MUTANT ACE2 PROTEINS AND METHODS OF USING SAME

 #13
20250009852
2025-01-09

DEPLETING EGFR AND HER2 OVERCOMES RESISTANCE TO EGFR INHIBITORS IN COLORECTAL CANCER

 #14
20240398911
2024-12-05

ENGINEERED RECEPTORS AND MONOCLONAL ANTIBODIES FOR CRONAVIRUSES AND USES THEREOF

 #15
20240398910
2024-12-05

METHODS AND COMPOSITIONS FOR THE TREATMENT OF CORONAVIRUS INFECTION, INCLUDING SARS-COV-2

 #16
20240392274
2024-11-28

ACTIVE LOW MOLECULAR WEIGHT VARIANTS OF ANGIOTENSIN CONVERTING ENZYME 2 (ACE2)

 #17
20240382569
2024-11-21

FUNGAL ENZYME MIXTURES AND USES THEREOF

 #18
20240352438
2024-10-24

MEANS AND METHODS FOR DETOXIFYING OCHRATOXIN A

 #19
20240335507
2024-10-10

THERAPEUTIC COMPOSITION FOR USE IN THE TREATMENT OF COVID-19 AND OTHER CYTOKINE STORM ASSOCIATED DISORDERS

 #20
20240307512
2024-09-19

ACE2-IgM-Fc FUSION PROTEINS AND USES THEREOF

 #21
20240293518
2024-09-05

METHOD FOR PROPHYLAXIS AND/OR TREATMENT OF ErbB2 POSITIVE CANCERS

 #22
20240173431
2024-05-30

NANOTHERAPEUTICS FOR TREATMENT OF SARS-COV-2

 #23
20240139296
2024-05-02

FORMULATIONS OF ACE2 FC FUSION PROTEINS

 #24
20240131124
2024-04-25

ANTIVIRAL STRUCTURALLY-STABILIZED ACE2 HELIX 1 PEPTIDES AND USES THEREOF

 #25
20240123097
2024-04-18

Dual-Mode Pharmaceutical Composition for Peptide-Specific Targeted Positron Emission Tomography and Boron Neutron Capture Therapy and the Use Thereof

 #26
20240115670
2024-04-11

FIBROBLAST ACTIVATION PROTEIN MODULATION TO ALTER IMMUNE CELL MIGRATION AND TUMOR INFILTRATION

 #27
20240091323
2024-03-21

ENGINEERED STABLE ACE2 PROTEIN VARIANTS AS ANTIVIRAL NEBULIZED THERAPEUTICS

 #28
20240052330
2024-02-15

BLOCKADE OF SARS-COV-2 INFECTION USING HYDROCARBON STAPLED PEPTIDES

 #29
20240018499
2024-01-18

ACE2 Fusion Proteins and Uses Thereof

 #30
20230364206
2023-11-16

GENE THERAPY FOR OCULAR MANIFESTATIONS OF CLN2 DISEASE

 #31
20230346848
2023-11-02

FIBROBLAST AND TLR ACTIVATED FIBROBLAST TREATMENT OF VIRAL INDUCED ACUTE RESPIRATORY DISTRESS SYNDROME

 #32
20230338478
2023-10-26

COMPOSITIONS AND METHOD OF USE OF MUTANT ACE2 DECOY VARIANTS

 #33
20230302101
2023-09-28

Compositions and methods for treatment of SARS-COV-2

 #34
20230293648
2023-09-21

STABILIZED ACE2 VARIANT, ACE2-FC FUSION PROTEIN USING SAME, AND METHOD FOR PREVENTING OR TREATING COVID-19

 #35
20230293647
2023-09-21

Polypeptide

 #36
20230218746
2023-07-13

COMPOSITIONS AND METHODS RELATING TO ANTIVIRAL THERAPEUTICS

 #37
20230210910
2023-07-06

METHOD FOR PREVENTING INFECTION OF A HEALTHY PERSON OR A HEALTHY ANIMAL WITH A VIRUS THAT USES ACE2 AS A RECEPTOR, BINDING INHIBITOR AND MEDICAL DEVICE

 #38
20230183668
2023-06-15

ACE2 MUTEINS AND METHODS OF USING THE SAME

 #39
20230181700
2023-06-15

ACE2 FC FUSION PROTEINS AND METHODS OF USE

 #40
20230145118
2023-05-11

Modified Red Blood Cells and Uses Thereof for Delivering Agents

 #41
20230127775
2023-04-27

METHODS AND COMPOSITIONS FOR THE TREATMENT OF AMYLOIDOSIS

 #42
20230101022
2023-03-30

GINSENOSIDE M1 AS A MODULATOR OF ANGIOTENSIN REGULATING ENZYMES AND ITS USE FOR TREATING DISEASES OR CONDITIONS INCLUDING SYMPTOMS CAUSED BY CORONAVIRUS

 #43
20230085357
2023-03-16

INJECTABLE HIGH CONCENTRATION PHARMACEUTICAL FORMULATIONS AND METHODS OF MANUFACTURING AND USE THEREOF

 #44
20230000956
2023-01-05

COMBINATION THERAPY WITH GLUCARPIDASE WITH METHOTREXATE/RITUXIMAB TO TREAT CNS LYMPHOMA

 #45
20220406435
2022-12-22

METHODS OF TREATING DEMENTIA ASSOCIATED WITH ALZHEIMER'S DISEASE WITH PROTECTIVE PROTEIN/CATHEPSIN A (PPCA)

 #46
20220305061
2022-09-29

COMPOSITIONS DERIVED FROM HUMAN AMNION CELLS & RELATED METHODS

 #47
20220273775
2022-09-01

Methods for Treating CLN2 Disease in Pediatric Subjects

 #48
20220257728
2022-08-18

USE OF HISTONE DEUBIQUITINASE IN PREPARING DRUG FOR PREVENTING AGING AND TREATING AGING-RELATED DISEASES

 #49
20220233659
2022-07-28

Oral delivery of angiotensin converting enzyme 2 (ACE2) or angiotensin-(1-7)-bioencapsulated in plant cells attenuates pulmonary hypertension, cardiac dysfunction and development of autoimmune and experimentally induced ocular disorders

 #50
20220184188
2022-06-16

AAV VECTOR TREATMENT METHODS FOR LATE INFANTILE NEURONAL CEROID LIPOFUSCINOSIS TYPE 2

 #51
20220175895
2022-06-09

Method for preventing or treating metabolic disorder

 #52
20220168404
2022-06-02

METHODS AND COMPOSITIONS FOR THE TREATMENT OF CORONAVIRUS INFECTION, INCLUDING SARS-COV-2

 #53
20220152165
2022-05-19

COMBINATION OF NASAL GENE DELIVERY AND ORAL CINNAMIC ACID, OLEAMIDE OR GEMFIBROZIL FOR LYSOSOMAL STOARGE DISORDERS

 #54
20220152164
2022-05-19

GPCR COMBINATION THERAPIES

 #55
20220137070
2022-05-05

METHODS AND SYSTEMS FOR IDENTIFYING MODULATORS OF PERVASIVE DEVELOPMENTAL DISORDERS

 #56
20220127614
2022-04-28

Compositions and methods for treating COVID-19

 #57
20220098243
2022-03-31

Selective recovery

 #58
20220088131
2022-03-24

COMPOSITIONS AND METHODS RELATING TO C5L2

 #59
20220056536
2022-02-24

Methods of modulating immune response

 #60
20220056429
2022-02-24

Angiotensin-converting enzyme 2 (ACE2) immunoadhesin microbody

 #61
20220047686
2022-02-17

METHODS FOR TREATING INFECTIOUS DISEASES

 #62
20220047017
2022-02-17

FACE MASKS AND OTHER PROTECTIVE DEVICES HAVING ENHANCED VIRUS ENTRAPMENT EFFICIENCY, AND RELATED METHODS

 #63
20220033794
2022-02-03

Active low molecular weight variants of angiotensin converting enzyme 2 (ACE2)

 #64
20220025349
2022-01-27

COMPOSITIONS AND METHODS FOR TREATING CANCER

 #65
20220023398
2022-01-27

COMPOSITIONS AND METHODS FOR TREATING THYROID DISEASE

 #66
20220016162
2022-01-20

COMPOSITIONS AND METHODS FOR TREATING BONE INJURY

 #67
20220002700
2022-01-06

COMPUTATIONALLY-OPTIMIZED ACE2 PEPTIDES FOR COMPETITIVE INTERCEPTION OF SARS-CoV-2

 #68
20210395744
2021-12-23

COMPOSITIONS AND METHODS FOR TREATING COVID-19

 #69
20210386837
2021-12-16

ACTIVE LOW MOLECULAR WEIGHT VARIANTS OF ANGIOTENSIN CONVERTING ENZYME 2 (ACE2) FOR THE TREATMENT OF DISEASES AND CONDITIONS OF THE EYE

 #70
20210386821
2021-12-16

Therapeutic composition for use in the treatment of COVID-19 and other cytokine storm associated disorders

 #71
20210371841
2021-12-02

Soluble ACE2 variants and uses therefor

 #72
20210369820
2021-12-02

METHOD FOR PROPHYLAXIS AND/OR TREATMENT OF ErbB2 POSITIVE CANCERS

 #73
20210299257
2021-09-30

Methods, Systems and Apparatus for Reducing Pathogen Loads in Circulating Body Fluids

 #74
20210228694
2021-07-29

METHODS AND COMPOSITIONS FOR THE TREATMENT OF AMYLOIDOSIS

 #75
20210220295
2021-07-22

TREATMENT OF CANCER BY GUANIDINIUM DERIVATIVES

 #76
20210213111
2021-07-15

Compositions and methods for treating pancreatitis

 #77
20210145943
2021-05-20

Oral delivery of angiotensin converting enzyme 2 (ACE2) or angiotensin-(1-7)-bioencapsulated in plant cells attenuates pulmonary hypertension, cardiac dysfunction and development of autoimmune and experimentally induced ocular disorders

 #78
20200353059
2020-11-12

TPP-1 formulations and methods for treating CLN2 disease

 #79
20200291373
2020-09-17

Treatment of a Condition Associated with Infection with an Oncogenic Bacterium

 #80
20200181594
2020-06-11

Active low molecular weight variants of angiotensin converting enzyme 2 (ACE2)

 #81
20200129448
2020-04-30

COMPOSITIONS AND METHODS FOR WOUND CLOSURE

 #82
20200121740
2020-04-23

PHARMACEUTICAL COMPOSITIONS CONTAINING PEDIOCOCCUS AND METHODS FOR REDUCING THE SYMPTOMS OF GASTROENTEROLOGICAL SYNDROMES

 #83
20200087704
2020-03-19

METHODS OF TREATING DEMENTIA ASSOCIATED WITH ALZHEIMER'S DISEASE WITH PROTECTIVE PROTEIN/CATHEPSIN A (PPCA)

 #84
20200087353
2020-03-19

Selective recovery

 #85
20190390203
2019-12-26

REDUCTION OF LIPASE ACTIVITY IN PRODUCT FORMULATIONS

 #86
20190374623
2019-12-12

TREATMENTS FOR HEART FAILURE AND CARDIAC ISCHAEMIC REPERFUSION INJURY

 #87
20190367902
2019-12-05

Bioresponsive particles

 #88
20190365869
2019-12-05

Bioresponsive Particles

 #89
20190358304
2019-11-28

Oral delivery of angiotensin converting enzyme 2 (ACE2) or angiotensin-(1-7)-bioencapsulated in plant cells attenuates pulmonary hypertensions, cardiac dysfunction and development of autoimmune and experimentally induced ocular disorders

 #90
20190292230
2019-09-26

Selective recovery

 #91
20190269797
2019-09-05

GENE TRANSFER COMPOSITIONS, METHODS AND USES FOR TREATING NEURODEGENERATIVE DISEASES

 #92
20190242909
2019-08-08

COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDER

 #93
20190216905
2019-07-18

TPP-1 formulations and methods for treating CLN2 disease

 #94
20190201488
2019-07-04

COMPOSITIONS AND METHODS RELATING TO C5L2

 #95
20190183985
2019-06-20

METHODS AND COMPOSITIONS FOR THE TREATMENT OF AMYLOIDOSIS

 #96
20190144509
2019-05-16

Selective recovery

 #97
20190134165
2019-05-09

COMPOSITIONS AND METHODS FOR TREATING THYROID DISEASE

 #98
20190117745
2019-04-25

DRUG DELIVERY METHOD

 #99
20190111117
2019-04-18

Method for prophylaxis and/or treatment of ErbB2 positive cancers

 #100
20190062697
2019-02-28

Cell Differentiation Marker and its Uses

 #101
20180289779
2018-10-11

Method for producing ACE2 polypeptide

 #102
20180275146
2018-09-27

COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDER

 #103
20180230447
2018-08-16

Active low molecular weight variants of angiotensin converting enzyme 2 (ACE2)

 #104
20180230186
2018-08-16

Selective recovery

 #105
20180200330
2018-07-19

Compositions and Methods for the Treatment of Diseases Related to the Renin-Angiotensin-System

 #106
20180179545
2018-06-28

Reduction of lipase activity in product formulations

 #107
20180117126
2018-05-03

TREATMENT OF INFLAMMATORY ILLNESSES WITH ACE2

 #108
20180085306
2018-03-29

Therapeutic compounds and formulations for intranasal delivery

 #109
20180057854
2018-03-01

Methods of treating dementia associated with Alzheimer's disease with protective protein/cathepsin A (PPCA)

 #110
20180009907
2018-01-11

NOVEL DIAGNOSTIC AND THERAPEUTIC TARGET IN INFLAMMATORY AND/OR CARDIOVASCULAR DISEASES

 #111
20170290894
2017-10-12

Compositions and methods for treating thyroid disease

 #112
20170240885
2017-08-24

Selective recovery

 #113
20170232078
2017-08-17

Method for prophylaxis or treatment of erbb1 positive cancers using a variant peptidase d with reduced activity

 #114
20170166926
2017-06-15

Targeting peptides for directing adeno-associated viruses (AAVs)

 #115
20170119861
2017-05-04

METHODS AND COMPOSITIONS FOR THE TREATMENT OF AMYLOIDOSIS

 #116
20170000729
2017-01-05

METHODS AND COMPOSITIONS FOR TREATMENT OF NEURODEGENERATIVE DISEASES

 #117
20160339086
2016-11-24

COMPOSITIONS AND METHODS FOR TREATING THYROID DISEASE

 #118
20160333334
2016-11-17

Crystals of angiotensin-converting enzyme (ACE)

 #119
20160331816
2016-11-17

Oral delivery of angiotensin converting enzyme 2 (ACE2) or angiotensin-(1-7) bioencapsulated in plant cells attenuates pulmonary hypertension, cardiac dysfunction and development of autoimmune and experimental induced ocular disorders

 #120
20160324942
2016-11-10

TPP-1 formulations and methods for treating CLN2 disease

 #121
20160317627
2016-11-03

PHARMACEUTICAL COMPOSITIONS CONTAINING PROTEASES AND METHODS FOR THE TREATMENT OF LYSOSOMAL STORAGE DISEASES

 #122
20160312226
2016-10-27

Reduction of lipase activity in product formulations

 #123
20160310562
2016-10-27

Compositions and methods for the treatment of diseases related to the renin-angiotensin-system

 #124
20160304933
2016-10-20

Methods and compositions to detect the level of lysosomal exocytosis activity and methods of use

 #125
20160271216
2016-09-22

COMPOSITIONS AND METHODS RELATING TO C5L2

 #126
20160271205
2016-09-22

Use of angiotensin II (AII) receptor agonists to prevent or reduce hemodialysis-associated skeletal muscle cramps

 #127
20160264933
2016-09-15

CELL DIFFERENTIATION MARKER AND ITS USES

 #128
20160199462
2016-07-14

Method for prophylaxis and/or treatment of ErbB2 positive cancers

 #129
20160193305
2016-07-07

Drug delivery method

 #130
20160115466
2016-04-28

ENZYME AND USES THEREOF

 #131
20160024206
2016-01-28

Methods for the Treatment and the Prognostic Assessment of Malignant Pleural Mesothelioma

 #132
20150353910
2015-12-10

Modified ACE2 polypeptides

 #133
20150329646
2015-11-19

NOVEL DIAGNOSTIC AND THERAPEUTIC TARGET IN INFLAMMATORY AND/OR CARDIOVASCULAR DISEASES

 #134
20150272920
2015-10-01

METHOD FOR TREATING OBESITY WITH ANTI-OBESITY FORMULATIONS AND OMEGA 3 FATTY ACIDS FOR THE REDUCTION OF BODY WEIGHT IN CARDIOVASCULAR DISEASE PATIENTS (CVD) AND DIABETICS

 #135
20150247138
2015-09-03

Enhanced staphylolytic activity of the bacteriophage vBSauS-philPLA88 virion-associated peptidoglycan hydrolase HydH5: fusions, deletions and synergy with LysH5

 #136
20150190472
2015-07-09

Use of the angiotensin-(1-9) peptide or derivatives thereof, use of vectors overexpressing the ACE2 enzyme that produces angiotensin-(1-9) for preparing medicaments useful for preventing, reverting, inhibiting and/or reducing hypertension and/or inducing vasodilation

 #137
20150118290
2015-04-30

METHOD FOR REDUCING ESTABLISHED METASTATIC TUMOR BY PHARMACEUTICAL COMPOSITION CONTAINING POLYPEPTIDE

 #138
20150079038
2015-03-19

Recombinant AAV capsid protein

 #139
20150023949
2015-01-22

COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDER

 #140
20140377245
2014-12-25

METHODS AND COMPOSITIONS TO DETECT THE LEVEL OF LYSOSOMAL EXOCYTOSIS ACTIVITY AND METHODS OF USE

 #141
20140328818
2014-11-06

Proteases for degrading gluten

 #142
20140271609
2014-09-18

Methods of treatment of cellulite

 #143
20140099297
2014-04-10

ACE2 POLYPEPTIDE

 #144
20140044694
2014-02-13

Pharmaceutical composition for treating lysosomal storage disease

 #145
20130295062
2013-11-07

METHODS AND COMPOSITIONS FOR TREATMENT OF ALZHEIMER'S DISEASE

 #146
20130216604
2013-08-22

POLYPEPTIDE FOR INHIBITING METASTASIS, USES THEREOF, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME

 #147
20130195884
2013-08-01

NOVEL MODULATORS OF TRAIL SIGNALLING

 #148
20130156884
2013-06-20

PROTEASE ENZYMES FOR INCREASED PROTEIN DIGESTION RATE AND ABSORPTION AND METHODS OF USING THE SAME

 #149
20130129697
2013-05-23

Enhanced staphylolytic activity of the bacteriophage vBSauS-philPLA88 virion-associated peptidoglycan hydrolase HydH5: fusions, deletions and synergy with LysH5

 #150
20130089536
2013-04-11

PHARMACEUTICAL COMPOSITION TO PREVENT AND TREAT ALZHEIMER'S DISEASE COMPRISING GCP II MUTANT

 #151
20130045195
2013-02-21

Proteases for Degrading Gluten

 #152
20130039897
2013-02-14

COMPOSITIONS AND METHODS FOR REGULATING NEUTROPHIL MOVEMENT AND NEUTROPHIL NUMBERS IN A BODY REGION

 #153
20130022981
2013-01-24

Human lysosomal protein and methods of its use

 #154
20120315263
2012-12-13

Pharmaceutical compositions containing protease and methods for the treatment of lysosomal storage diseases

 #155
20120276075
2012-11-01

SYNERGIC ACTION OF A PROLYL PROTEASE AND TRIPEPTIDYL PROTEASES

 #156
20120251520
2012-10-04

ACE2 activation for treatment of heart, lung and kidney disease and hypertension

 #157
20120164128
2012-06-28

MEANS AND METHODS FOR COUNTERACTING POLYQ EXPANSION DISORDERS

 #158
20120156253
2012-06-21

Enzyme treatment of foodstuffs for celiac sprue

 #159
20120156189
2012-06-21

Skin cosmesis treatment with clostridia neurotoxins

 #160
20120114697
2012-05-10

TREATMENT OF HOLOCRINE GLAND DYSFUNCTION WITH CLOSTRIDIA NEUROTOXINS

 #161
20120083004
2012-04-05

Diagnostic method for celiac sprue

 #162
20120014935
2012-01-19

Methods of treating a deficiency of functional tripeptidyl peptidase I (CLN2) protein

 #163
20110301186
2011-12-08

USE OF HAPTOGLOBIN GENOTYPING IN DIAGNOSIS AND TREATMENT OF CARDIOVASCULAR DISEASE

 #164
20110300161
2011-12-08

Methods for the treatment and the prognostic assessment of malignant pleural mesothelioma

 #165
20110293724
2011-12-01

Enzyme treatment of foodstuffs for celiac sprue

 #166
20110256120
2011-10-20

Method of increasing cathepsin B-induced cleavage of amyloid-β peptides

 #167
20110256097
2011-10-20

Treatment of Conditions that Increase in Severity and/or Occurrence During One or More Phases of the Menstrual Cycle

 #168
20110171294
2011-07-14

Enzyme composition and application thereof in the treatment of pancreatic insufficiency

 #169
20110166074
2011-07-07

CLN2 TREATMENT OF ALZHEIMER'S DISEASE

 #170
20110123573
2011-05-26

Methods and compositions for treating phenylketonuria

 #171
20110033524
2011-02-10

Treatment of tumors

 #172
20110033463
2011-02-10

APHERESIS, ADMINISTRATION OF AGENT, OR COMBINATION THEREOF

 #173
20110020315
2011-01-27

Treatment of inflammatory illnesses with ACE2

 #174
20110014172
2011-01-20

Methods of treating a deficiency of functional tripeptidyl peptidase I (CLN2) protein

 #175
20100322912
2010-12-23

Combination Enzyme Therapy for Gastric Digestion of Dietary Gluten in Celiac Sprue Patients

 #176
20100317025
2010-12-16

Diagnostic method for celiac sprue

 #177
20100316624
2010-12-16

TREATMENT OF FIBROSES AND LIVER DISORDERS

 #178
20100311822
2010-12-09

ACE2 activation for treatment of heart, lung and kidney disease and hypertension

 #179
20100310546
2010-12-09

Recombinant ACE2 polypeptide dimer

 #180
20100273989
2010-10-28

ANGIOTENSIN CONVERTING ENZYME HOMOLOG AND USES THEREFOR

 #181
20100173977
2010-07-08

Crystal structure of the N-terminal domain of angiotensin converting enzyme and uses thereof

 #182
20100129343
2010-05-27

Use Of A Compound For Enhancing The Expression Of Membrane Proteins On The Cell Surface

 #183
20100119482
2010-05-13

Treatment of Conditions Through Modulation of the Autonomic Nervous System During at Least One Predetermined Menstrual Cycle Phase

 #184
20100098713
2010-04-22

27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552 and 65577 molecules and uses therefor

 #185
20100003237
2010-01-07

Methods of treatment of collagen-mediated diseases and conditions

 #186
20090298771
2009-12-03

USE OF SECRETED PROTEIN PRODUCTS FOR PREVENTING AND TREATING PANCREATIC DISEASES AND/OR OBESITY AND/OR METABOLIC SYNDROME

 #187
20090280555
2009-11-12

ENZYME TREATMENT OF FOODSTUFFS FOR CELIAC SPRUE

 #188
20090175831
2009-07-09

ADAPTABLE MESSENGER RIBONUCLEIC ACID MEDICAL TREATMENT DEVICE TO MANAGE DIABETES MELLITUS

 #189
20090137617
2009-05-28

USE OF HAPTOGLOBIN GENOTYPING IN DIAGNOSIS AND TREATMENT OF CARDIOVASCULAR DISEASE

 #190
20090081206
2009-03-26

METHOD AND PHARMACEUTICAL COMPOSITION FOR INHIBITING PREMATURE RAPTURE OF FETAL MEMBRANES, RIPENING OF UTERINE CERVIX AND PRETERM LABOR IN MAMMALS

 #191
20090075315
2009-03-19

Human lysosomal protein and methods of its use

 #192
20090022701
2009-01-22

Methods of reducing storage products using tripeptidyl peptidase I (CLN2) protein

 #193
20080234468
2008-09-25

27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552 and 65577 molecules and uses therefor

 #194
20080213822
2008-09-04

Methods for diagnosing celiac sprue and reagents useful therein

 #195
20080213427
2008-09-04

Enzyme treatment of foodstuffs for celiac sprue

 #196
20080213245
2008-09-04

Enzyme treatment of foodstuffs for Celiac Sprue

 #197
20080193436
2008-08-14

Therapeutic enzyme formulations and uses thereof in celiac sprue and/or dermatitis herpetoformis

 #198
20080160008
2008-07-03

Methods and compositions for reducing amyloid beta levels

 #199
20080159962
2008-07-03

Use of Inhibitors of the Renin-Angiotensin System for the Treatment of Lung Injuries

 #200
20080145356
2008-06-19

Enzyme treatment of foodstuffs for celiac sprue

 #201
20080112944
2008-05-15

COMPOSITIONS AND METHODS FOR THE TREATMENT OF AUTISM

 #202
20080095710
2008-04-24

Enzyme treatment of foodstuffs for celiac sprue

 #203
20080051358
2008-02-28

Method of expressing human lysosomal protein in brain cells

 #204
20070248579
2007-10-25

Use of Secreted Protein Products for Preventing and Treating Pancreatic Diseases and/or Obesity and/or Metabolic Syndrome

 #205
20070243182
2007-10-18

Use of Carboxypeptidease G for Combating Antifolate Toxicity

 #206
20070218043
2007-09-20

Use of a compound for enhancing the expression of membrane proteins on the cell surface

 #207
20070122384
2007-05-31

Method for treating inflammatory bowel disease

 #208
20070092501
2007-04-26

Compositions and methods relating to reduction of symptoms of autism

 #209
20070077641
2007-04-05

Methionine aminopeptidase and methods of use

 #210
20070071724
2007-03-29

Peptide having hydrolase activity

 #211
20070065433
2007-03-22

Methods and compositions for the treatment of meconium aspiration syndrome

 #212
20070020327
2007-01-25

Inducing cellular immune responses to prostate cancer antigens using peptide and nucleic acid compositions

 #213
20060240475
2006-10-26

Diagnostic method for Celiac Sprue

 #214
20060240464
2006-10-26

27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552, and 65577 molecules and uses therefor

 #215
20060239993
2006-10-26

Drug containing angiotensin convertase

 #216
20060134088
2006-06-22

Enzymatic treatment of retinitis pigmentosis

 #217
20060115467
2006-06-01

Compositions and methods for the treatment of autism

 #218
20060104946
2006-05-18

Method for treating inflammatory bowel disease

 #219
20060051366
2006-03-09

Use of soluble CD26 as inhibitor of angiogenesis and inflammation

 #220
20060045874
2006-03-02

Aminoglycoside treatment for lysosomal storage diseases

 #221
20060008454
2006-01-12

Use of a compound for enhancing the expression of membrane proteins on the cell surface

 #222
20050288215
2005-12-29

Inhibition of nuclear export as a treatment for cardiac hypertrophy and heart failure

 #223
20050256028
2005-11-17

Treatment of conditions through modulation of the autonomic nervous system during at least one predetermined menstrual cycle phase

 #224
20050251873
2005-11-10

ACE2 activation for treatment of heart, lung and kidney disease and hypertension

 #225
20050249719
2005-11-10

Enzyme treatment of foodstuffs for Celiac Sprue

 #226
20050220820
2005-10-06

Treatment of holocrine gland dysfunction with clostridia neurotoxins

 #227
20050220790
2005-10-06

Amino-terminally truncated rantes as chemokine antagonists

 #228
20050201977
2005-09-15

Amino-terminally truncated MCP-2 as chemokine antagonists

 #229
20050164936
2005-07-28

Use of amino-terminally truncated RANTES to inhibit HIV viral replication

 #230
20050163771
2005-07-28

Method and pharmaceutical composition for inhibiting premature rapture of fetal membranes, ripening of uterine cervix and preterm labor in mammals

 #231
20050153906
2005-07-14

Aminoglycoside treatment for lysosomal storage diseases

 #232
20050147600
2005-07-07

Angiotensin converting enzyme homolog and uses therefor

 #233
20050025722
2005-02-03

Removing dental plaque with krill enzymes